

**SODIUM CHROMATE 51 - sodium chromate 51 solution**  
**AnazaoHealth Corporation**

*Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.*

-----

**Sodium Chromate 51**

Per your order, we have compounded Chromium 51 as a sterile intravenous injectable dispensed as 1 mL in a 5 mL vial. The characteristics of this preparation are described below

**DESCRIPTION**

AnazaoHealth's compounded Cr-51 vial is a sterile, non-pyrogenic diagnostic radiopharmaceutical that consists up to 1 mCi of Cr-51 (precalibrated) in a volume up to 5 mL normal saline and 6 mg/mL benzyl alcohol.

**INDICATIONS AND USAGE**

Cr51 is indicated for use in determining red blood cell volume or mass, studying red blood cell survival time (in conditions such as hemolytic anemia), and evaluating blood loss

**Mechanism of Action**

The chromium in this agent is present as the dianionic chromate ion in which form it appears to bind to the red blood cell in two steps, initially by a rapid but reversible attachment to the cell membrane followed by a slower nearly irreversible binding to intracellular hemoglobin and reduction to the anionic state. It has been suggested that the slow rate of uptake is dependent on the rate at which chromate can penetrate the cell membrane. Binding is maintained until the red blood cells are sequestered by the spleen or until elution of the chromium occurs into the plasma. The chromium is then readily excreted mainly in the urine. Once liberated by elution or erythrocyte senescence, chromium 51 is not available for relabeling of red cells.

In normal individuals the erythrocyte survival half-time  $T_{1/2}$  as measured by the chromium 51 "random labeling" technique, generally ranges between 25 and 35 days. This apparent short survival time, when compared to the 120 day life span of the red blood cells, is due to the elution of chromium from the cells and to cell damage that probably occurs during the process of withdrawing them from the body and labeling. Subnormal  $T_{1/2}$  may be indicative of blood loss, sequestration of red blood cells by the spleen, or shortened cell viability, as occurs in hemolytic anemia

**CONTRAINDICATIONS**

There are no known contraindications for this preparation

**DOSAGE AND ADMINISTRATION**

- The suggested dose range in the average patient (70kg) is:  
Determination of red blood cell volume or mass-0.37 to 1.11 megabecquerels (10 to 30 microcuries).
- Study of red blood cell survival time-5.55 megabecquerels (150 microcuries).
- Evaluation of blood loss-7.40 megabecquerels (200 microcuries)

Figure 1

**Cr51 Physical Decay Chart (half life 27.7 days)**

Days	Fraction remaining
0	1
1	0.975
2	0.951
3	0.928
4	0.905

**PACKAGE LABEL.PRINCIPAL DISPLAY PANEL**

Figure 2

**51 Chromium Chromate 100uCi/mL**

Normal Saline    Benzyl Alcohol 6 mg/mL

**Lot #**                      **Cal:**                      **Exp:**  
 Pharmacy Compounded    Sterile, non-pyrogenic for injection



5710 Hoover Blvd., Tampa, FL 33634  
 Phone (800)995-4363 Fax (800)697-5250

**SODIUM CHROMATE 51**

sodium chromate 51 solution

**Product Information**

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:51808-101
<b>Route of Administration</b>	INTRAVENOUS		

**Active Ingredient/Active Moiety**

Ingredient Name	Basis of Strength	Strength
CHROMIUM CR-51 (UNII: 9QAU17N705) (CHROMIUM CR-51 - UNII:9QAU17N705)	CHROMIUM CR-51	1 mCi in 5 mL

**Inactive Ingredients**

Ingredient Name	Strength
BENZYL ALCOHOL (UNII: LKG8494WBH)	30 mg in 5 mL
SODIUM CHLORIDE (UNII: 451W47IQ8X)	

**Packaging**

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:51808-101-02	5 mL in 1 VIAL		

**Marketing Information**

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Unapproved drug other		06/19/2012	

**Labeler** - AnazaoHealth Corporation (011038762)**Establishment**

Name	Address	ID/FEI	Business Operations
AnazaoHealth Corporation		011038762	MANUFACTURE(51808-101)

Revised: 6/2012

AnazaoHealth Corporation